| INTRODUCTION
Liver disease is a major cause of morbidity and mortality in dogs. 1 To reach a definitive diagnosis clinicians measure a panel of biochemical blood variables to identify dogs that would benefit from subsequent imaging and histopathological evaluation of liver biopsy specimens.
The most commonly used circulating biochemical indicators of liver injury are alanine aminotransferase activity (ALT), aspartate aminotransferase activity (AST), alkaline phosphatase activity (AP), and gamma-glutamyltransferase activity (GGT). However, these current biochemical assays have sub-optimal sensitivity and specificity for detection of histologically confirmed liver disease. 2 Consequently, only ALT, which is present in high concentrations within the cytoplasm and mitochondria of canine hepatocytes, is widely used to assess dogs for the presence of liver injury and has emerged as the gold-standard marker of hepatocellular injury. The degree of increased serum ALT activity is roughly proportional to disease severity, but ALT might not increase ("false negative") in a number of different scenarios such as reduced hepatocyte number due to advanced fibrosis, non-inflammatory primary or secondary neoplasia, and early in the course of hepatocellular disease. 3, 4 Other non-liver diseases (eg, diabetes mellitus and hemolysis) might also result in elevated serum ALT activity. 3, 4 In 191 clinically healthy labradors with histopathological abnormalities in the liver, the sensitivity of ALT and AP was only 45%
(95% CI: 25%-65%) and 15% (0%-35%), respectively, for reporting acute hepatitis. 2 In the setting of chronic hepatitis, sensitivity was 71% (47%-94%) and 13% (0%-31%), respectively, for ALT and AP. 2 For most liver diseases, histopathological evaluation of liver biopsy samples is needed for a definitive diagnosis and is used as the reference standard against which the accuracy of the other tests is compared. However, biopsy remains an invasive, costly procedure with associated risks of complications from the procedure. For example, a retrospective study demonstrated that 4% of dogs undergoing liver biopsy required a post-procedure blood transfusion. 5 In summary, there is a clear and urgent need to develop better diagnostic tests that will allow clinicians to diagnose liver disease in dogs earlier, and more accurately target invasive liver biopsy to dogs with a high likelihood of having serious liver disease.
MicroRNAs (miRNAs) are small (~22 nucleotide-long) non-protein coding RNAs that regulate post-transcriptional gene expression. 6 The properties of circulating microRNAs that support their utility as biomarkers include organ specificity (for certain microRNA species), relative stability in blood and their ability to be amplified and measured by polymerase chain reaction (PCR). miR-122 is highly expressed in hepatocytes accounting for up to 70% of the total liver miRNA content. 7 Multiple studies have demonstrated the sensitivity and specificity of miR-122 as a circulating biomarker of liver injury in chimpanzees, 8 mice, 9 rats, 10 zebrafish, 11 and in human studies of different liver diseases including drug-induced liver injury (DILI), 12 hepatitis C, 13 and ethanol consumption. 14 miR-122 has received regulatory support for further qualification by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the context of DILI. 15, 16 Importantly, miR-122 has enhanced sensitivity and specificity when compared with standard biomarkers. For example, miR-122 accurately reports human DILI after acetaminophen overdose at first presentation to hospital at a time when current markers, such as ALT, are still within normal ranges. 17, 18 In dogs there have been a limited number of studies that suggest circulating miR-122 could have utility in diagnosing liver disease. In a pre-clinical drug development study, ALT was elevated in the absence of abnormal liver histology in beagles. 19 In this study miR-122 was measured and had increased specificity with regard to excluding important histological liver abnormality. In a study of 66 Labrador retrievers, miR-122 was reported to be a specific and sensitive biomarker for liver injury and copper accumulation. 20 The same research group reported that circulating miR-122 is particularly elevated in Labrador retrievers with mucoceles. 21 These discovery studies investigated only small numbers of a single breed of dog, namely labradors, and were insufficiently sized to determine the normal reference interval for miR-122. Also, they did not include unwell dogs with non-liver pathology (an important control population needed to establish biomarker specificity). Building on our biomarker qualification experience in humans, the aims of this study were to establish the reference interval for serum miR-122 concentration in healthy dogs and then determine the sensitivity and specificity of miR-122 as a biomarker of liver injury across multiple dog breeds. clinical evaluation and had a residual serum sample retained were also enrolled into the study. Finally, consecutive dogs that had a diagnostic assessment which included histopathological examination of a liver biopsy and serum ALT measurement leading to definitive diagnosis of a primary liver disorder were enrolled into the study. The histopathological diagnosis was classified according to World Small Animal Veterinary Association (WSAVA) criteria by a board certified pathologist. 22 The study was approved by The University of Edinburgh Veterinary Ethics Research Committee.
| RNA isolation
Serum samples were stored at −80 C until miRNA analyses. The median time in storage between blood sampling and RNA isolation was 402 days (IQR: 207-593, n = 250) with 1091 days being the maximum storage time. This is less time in storage compared with published studies that demonstrate miRNA stability when frozen. 23, 24 miRNA was extracted using a miRNeasy Serum/Plasma kit (Qiagen, Venlo, Netherlands) following the manufacturer's instructions. Total RNA was extracted from 50 μL of serum diluted in 150 μL nuclease free water. Briefly, RNA was extracted from the serum by lysis reagent (1000 μL) and chloroform (200 μL). After centrifugation at 12 000g for 15 min at 4 C up to 600 μL of the aqueous phase was transferred to a new tube with 900 μL absolute ethanol. RNA was purified on a RNeasy minElute spin column and eluted in 15 μL
RNase-free water and stored at −80 C. Extraction efficiency was monitored by adding 5.6 × 10 8 copies of synthetic C. elegans miR-39
spike-in control after the addition of lysis reagent before the addition of chloroform and phase separation.
| Reverse transcription and real-time polymerase chain reaction (RT-PCR)
The miScript II Reverse Transcription kit was used to prepare cDNA according to the manufacturer's instructions. Briefly, 2.5 μL of RNA eluate was reverse transcribed into cDNA. The synthesised cDNA was diluted and used for cDNA template in combination with the miScript SYBR Green PCR kit (Qiagen, Venlo, The Netherlands) using the specific miScript assays (Qiagen, Venlo, The Netherlands). RT-PCR was performed in duplicate on a Light Cycler 480 (Roche, Burgess Hill, UK) using the recommended miScript cycling parameters.
In the current study, miRNA was quantified as copy number per μL by generating a standard curve. A calibration curve of C q as a function of miRNA was determined by performing PCR on miR-39 at 5 × Repeatability was determined by measuring the intra-assay variability of miR-122 duplicates and was deemed acceptable as per previous studies 25 
| Sample size
The International Federation of Clinical Chemistry (IFCC) recommends that samples from 120 or more individuals are required for the development of reference intervals for analytes. 27 
| Statistical analyses
Data were summarized as median and range for summary statistics of the study subjects. Serum miR-122 concentrations from healthy dogs were used to calculate the overall reference intervals following recommended approaches. 28, 29 The following three R packages were used:
Outliers, 30 jmuOutlier, 31 and Quantreg. 32 Firstly, the distribution of miR-122 concentrations was investigated using visual inspection of QQ plots to determine whether it required a log or square root transformation. The appropriate transformation was applied, if required, to the miR-122 concentrations to approximate a Gaussian distribution, fulfilling the normality assumption of subsequent analyses. Outliers were identified and removed according to Tukey's method. 33 The distribution of the miR-122 concentrations, transformed (if appropriate) and with outliers removed, was inspected for an approximate Gaussian distribution before references intervals were calculated. The 2.5th
and 97.5th quartiles were derived in order to calculate the 95% reference intervals for miR-122 concentration. The 90% confidence intervals (CI) for the reference intervals were calculated through nonparametric methods. method. 35 Normally distributed data were presented as mean AE standard deviation and non-normally distributed data as median and interquartile range. Nominal P values equal to or less than.05 were considered significant. Statistical analyses were performed using Graphpad Prism (GraphPad Software, La Jolla, California).
3 | RESULTS
| Dog characteristics
Serum samples from 250 dogs were analyzed (120 healthy, 100 with non-liver diseases, and 30 with histologically confirmed liver disease).
Characteristics of the healthy dogs including sex, age, breed, and clinical chemistry results are summarized in Table 1 Table 2 .
| Reference intervals of miR-122 in healthy dogs
Firstly, we investigated whether breed, sex, age, and weight in healthy dogs influenced circulating miR-122 concentrations. There were no significant differences in miR-122 concentration across the different breeds (breeds with more than three dogs per group are presented in Figure 1A ). Similarly, there was no difference between female and male dogs in this healthy cohort ( Figure 1B) . No significant relationship was found between circulating miR-122 concentration and dog body weight or age ( Figure 1C,D) . Secondly, we determined the reference interval for circulating miR-122 in healthy dogs (n = 120, as per IFCC guidelines). The data were normalized by a log transformation. After transformation, two values were removed as outliers (values: 8121 and 6651 copies/μL).
The distribution of miR-122 in healthy dogs is presented in Supporting
Information Figure S1 . The 2.5th, 50th, and 97.5th quartile of miR-122 were 110 (80-114), 594 (505-682), and 3312 (2925-5144) copies/μL, respectively. The 97.5th quartile represents the upper limit of normal (ULN) for this reference population.
| miR-122 serum concentrations in dogs with disease
Circulating miR-122 was measured in the three groups of dogs In the present study, we were the first to establish a normal reference interval of circulating miR-122 concentrations in healthy dogs across several different dog breeds. Interestingly, this reference interval is comparable to the normal reference interval in humans, 36 which might reflect this microRNA's concentration in the circulation being under tight regulation. However, the mechanism of miR-122 release into, and clearance from, the circulation in healthy animals remains undefined. We were also able to demonstrate that there were no significant differences in miR-122 concentrations across different age-, sex-, and dog breed groups, which in turn further enhances the current literature available on circulating miR-122 concentrations in dogs.
These findings build on previous studies which have reported no differences in miR-122 concentration between female and male dogs and no age-related differences. 20 Previously, the available literature Secondly, circulating miR-122 was able to discriminate between dogs with liver disease and both healthy dogs and dogs with non-liver
FIGURE 3 miR-122 concentration in liver disease. (A) Increased miR-122 concentration in fibrotic (n = 6), inflammatory (n = 19) and neoplastic (n = 5) etiologies of liver disease compared to healthy dogs (n = 120) as determined by one-way Kruskal-Wallis ANOVA (P = .02 healthy vs fibrotic, P = .0006 healthy vs inflammatory and P = .05 healthy vs neoplastic, respectively). There was no difference in miR-122 concentration across the liver pathology groups (P = .92 fibrotic vs inflammatory, P = .30 fibrotic vs neoplastic and P = .27 inflammatory vs neoplastic group) as determined by one-way Kruskal-Wallis ANOVA. Data are presented as Tukey plots. (B) There was a significant relationship between mir-122 concentration and ALT as determined by correlation and linear regression (P = .005, Spearman r = .49, n = 30)
Circulating miR-122 concentration in healthy dogs (n = 120) and in dogs with non-liver diseases (n = 100) and liver disease (n = 30). Data are presented as Tukey plots. The significance of differences between the groups were determined by one-way Kruskal-Wallis ANOVA disease with a significantly higher miR-122 concentration in the liver disease dog cohort. The sensitivity and specificity of miR-122 was comparable to our human studies of patients with acetaminophen toxicity but the dogs with liver disease in this study were heterogeneous with regard to the underlying disease etiology. This supports miR-122 having a potential context of use as a screening tool for liver disease in dogs.
The results from this study are a promising step in further developing circulating miR-122 as a qualified biomarker of liver disease in dogs.
It remains to be conclusively determined as to whether miR-122 can accurately detect liver disease when current markers such as ALT are still in their respective reference interval (a specific context of use for miR-122 in humans). In the present study we could not test this as the diagnosis of liver disease was already made using ALT to indicate need for liver biopsy. Future studies with prospective, serial, blood sampling are needed to determine the clinical utility of miR-122 in dogs. However, published work in Labradors supports miR-122 reporting liver disease when ALT is still in its normal reference interval. 20 Furthermore, as microRNA biomarkers are translatable across species, we believe it is justifiable to cautiously extrapolate human and rodent data to veterinary practice. In humans 16 and mice 9 , it is conclusively demonstrated that miR-122 is more sensitive than ALT, at least in the context of DILI.
We would predict the same performance in dogs and the present study would suggest utility across a range of liver diseases. An important hurdle to overcome is developing a point-of-care assay that clinicians could use to measure miR-122 in a timely and cost-efficient manner. The "market pull" from both human medicine and drug development has resulted in promising assays that could be applied to veterinary medicine because of the sequence conservation of miR-122. 37 In summary, miR-122 is a sensitive and specific biomarker for liver disease in dogs. With further development it could become a valuable tool in the diagnostic evaluation and treatment pathway of dogs with suspected liver disease.
ACKNOWLEDGMENTS
The work was done at University of Edinburgh.
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
[Correction added after first online publication 31 August 2018: Previous sentence wording has been changed]
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
The study was approved by 
